Polysubstituted Pyridine Compounds Inhibiting HIV Reverse Transcriptase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-HIV drugs face challenges with drug resistance, necessitating the development of new compounds with novel structures and mechanisms to effectively inhibit both wild-type and multidrug-resistant HIV strains.
Innovation Solution
Development of 2-(4-substituted phenylamino) polysubstituted pyridine compounds, specifically targeting HIV replication through novel chemical structures and mechanisms, which are synthesized via specific reaction routes and coupled with polysubstituted phenols or phenylamines to enhance their anti-HIV activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-HIV drugs are used, then HIV replication is inhibited, but drug resistance develops
Solution Approach 1:
The patent divides the existing drug class into multiple distinct chemical series (pyridine compounds, pyrimidine compounds, triazine compounds, etc.), each with unique structures and mechanisms. This segmentation allows different drugs to target different aspects of HIV replication, reducing the development of resistance to any single agent.
Solution Approach 2:
The patent employs combination therapy using composite regimens of multiple antiretroviral drugs from different chemical classes (e.g., NRTIs combined with NNRTIs, PIs, or entry inhibitors). This composite approach creates multiple simultaneous barriers to viral replication, making it difficult for the virus to develop resistance to all components.
2Reliability
If existing anti-HIV drugs are used, then treatment effectiveness is achieved, but high frequency dosing is required
Solution Approach 1:
The patent modifies pharmacokinetic parameters of antiretroviral drugs through structural optimization and formulation development. This includes extending half-lives of drugs, improving bioavailability, and developing long-acting formulations (such as injectable or depot preparations) that maintain therapeutic levels for extended periods, thereby reducing dosing frequency from multiple daily doses to once-weekly or less frequent administration.
3Adaptability or versatility
If new anti-HIV compounds are developed, then novel mechanisms of action are achieved, but manufacturing complexity increases
Solution Approach 1:
The patent organizes complex novel compounds into systematic chemical series (pyridine, pyrimidine, triazine, etc.) with modular structures. This segmentation allows for standardized synthesis pathways and facilitates manufacturing by breaking down complex molecules into manageable building blocks that can be produced using established chemical processes.
Data Source
AI summary
The invention relates to 2-(4-Substituted phenylamino) polysubstituted pyridine compounds as inhibitors of non-nucleoside HIV reverse transcriptase, preparation methods and uses thereof. Specifically, the invention relates to compounds of formula I or the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the description. The compounds of formula I of the invention are a type of anti-HIV active compounds having new backbone structure.